Eric Nuermberger

PROFESSOR

19992018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 14 Similar Profiles
Tuberculosis Medicine & Life Sciences
rifapentine Medicine & Life Sciences
Pyrazinamide Medicine & Life Sciences
Mycobacterium tuberculosis Medicine & Life Sciences
Rifampin Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Multidrug-Resistant Tuberculosis Medicine & Life Sciences
bedaquiline Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2018

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis

Leung-Theung-Long, S., Coupet, C. A., Gouanvic, M., Schmitt, D., Ray, A., Hoffmann, C., Schultz, H., Tyagi, S., Soni, H., Converse, P. J., Arias, L., Kleinpeter, P., Sansas, B., Mdluli, K., Vilaplana, C., Cardona, P. J., Nuermberger, E., Marchand, J. B., Silvestre, N. & Inchauspé, G., May 1 2018, In : PLoS One. 13, 5, e0196815

Research output: Contribution to journalArticle

Vaccinia
Vaccinium
Mycobacterium tuberculosis
Combination Drug Therapy
drug therapy

Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis

Ammerman, N. C. , Swanson, R. V. , Bautista, E. M. , Almeida, D. V. , Saini, V. , Omansen, T. F. , Guo, H. , Chang, Y. S. , Li, S. Y. , Tapley, A. , Tasneen, R. , Tyagi, S. , Betoudji, F. , Moodley, C. , Ngcobo, B. , Pillay, L. , Bester, L. A. , Singh, S. D. , Chaisson, R. E. , Nuermberger, E. & 1 others Grosset, J. H., Jul 1 2018, In : Antimicrobial Agents and Chemotherapy. 62, 7, e00636-18

Research output: Contribution to journalArticle

Clofazimine
Tuberculosis
Pharmaceutical Preparations
Therapeutics
Multidrug-Resistant Tuberculosis

Long-acting formulations for the treatment of latent tuberculous infection: Opportunities and challenges

Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., Nuermberger, E., Kim, P., Barry, C. E., Owen, A., Hazuda, D. & Flexner, C., Feb 1 2018, In : International Journal of Tuberculosis and Lung Disease. 22, 2, p. 125-132 8 p.

Research output: Contribution to journalReview article

Tuberculosis
Infection
HIV
Drug Compounding
Virus Diseases

Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis

Xu, J., Tasneen, R., Peloquin, C. A., Almeida, D. V., Li, S. Y., Barnes-Boyle, K., Lu, Y. & Nuermberger, E., Jan 1 2018, In : Antimicrobial Agents and Chemotherapy. 62, 1, e01692

Research output: Contribution to journalArticle

bedaquiline
Clofazimine
Verapamil
Mycobacterium tuberculosis
Biological Availability

Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

Li, S. Y., Tasneen, R., Tyagi, S., Soni, H., Converse, P. J., Mdluli, K. & Nuermberger, E. L., Sep 1 2017, In : Antimicrobial Agents and Chemotherapy. 61, 9, e00913-17

Research output: Contribution to journalArticle

bedaquiline
Pyrazinamide
Tuberculosis
Drug Combinations
Recurrence